Qubigen retweeted
Qubigen won Gold in Medical at the 2026 AFR BOSS Most Innovative Companies Awards.
While the big agentic AI and frontier lab deals (Xairaโs X-Scientist, OpenAIโs Orchestra Bio acquisition, AZโinsitro) get the headlines, the hard constraint remains the same: most models still need either public data or private project data that leaves the lab.
Qubigen retweeted
Congrats to @DrJMMHall and the @QubigenOps @qubigen team for winning Gold in the AFR Most Innovative Companies 2026 Awards for their novel AI platform which enables AI for drug design without compromising stakeholder privacy or intellectual property.
afr.com/life-and-luxury/healโฆ
Qubigen retweeted
โWinning gold in the Medical category of the Financial Review BOSS Most Innovative Companies awards, Qubigenโs AI tool can learn from a trove of pharmaceutical lab investigations, all without copying or sharing the data.โ
See link to the full article in the comments below ๐
Qubigen retweeted
๐จ ๐จ On Wednesday Night, @qubigen was named the Gold winner in the Medical category of The Australian Financial Review AFR BOSS Most Innovative Companies Awards, taking out the top spot of this National competition! ๐
This recognition reflects the groundbreaking work our team is doing to pioneer decentralised intelligence in drug discovery: building a platform that allows research labs to learn from their own high-value results without ever compromising, copying, or sharing raw data.
A huge congratulations ๐ฅ and thank you to our all-star team who made this possible: Sonya Diakiw (CSO), A/Prof Jun Zeng FRACI (CIO), Andrew Murphy (CTO), David Brooks (Operations Manager), Dr Tuc Van Nguyen (Senior Machine Learning Engineer), and Joshua Spender (Senior Software Engineer).
Special thanks to our board of directors for their continued support and backing, SYNthesis BioVentures, Prof. Andrew Wilks , Dr Amir Zalcenstein, Dr Fabio Turatti, James Roche, Chair Dr Michelle Perugini and our Corp Sec Rosemarie Singson.
Thank you to our advisors Matt Oristano, Trevor Thompson, Eric Hayes, and finally, to all the research and commercial partners who have worked with us and continue to collaborate with us on live projects.
Qubigen retweeted
Federated AI Engines for drug design enable secure collaboration, transcending institutional data firewalls. Qubigen's FedAIDD can leverage global data without actually moving or seeing it, to build the most intelligent, secure, disease-agnostic AI engines in drug design.
Qubigen retweeted
. @qubigen is heading to San Francisco for J.P. Morgan Healthcare Week 2026 (11โ15 January)! ๐บ๐ธ ๐ฆ๐บ๐จ
Proud to be part of the Australian Biotech Delegation, supported by Global Victoria. Weโll be actively partnering at BIO One-on-One, ABD Capital Connect sessions, and around Union Square.
Our Federated AI/ML platform is already accelerating drug design for pharma and CRO partners, collapsing hit-to-lead from years to weeks, securely and at fraction of the cost.
If youโre attending and interested in AI-enabled drug design or Series A discussions, letโs connect!
Reach me via BIO Partnering, ABD, or DM here.
Excited to build new bridges Down Under in the Bay Area.
Qubigen retweeted
Weโre excited to introduce the next group of Xtalks Featured Community Members, celebrating the people advancing life sciences across pharma, biotech, medtech, healthcare and beyond. Our newest members include:
ยท Christopher Missling, PhD, President & CEO, Anavex Life Sciences
ยท Jonathan Hall, PhD, Founder & CEO, Qubigen
ยท Mark Franklin, Manager, Curation, DrugBank
ยท Petra Elischer, Head of Quality and Regulatory Affairs, Hart Biologicals Limited
ยท Rebecca Starkie, Consultant, Civia Health
Meet them all at buff.ly/LSA0I1d and learn how to apply or nominate a colleague at buff.ly/LdsbLY7.
#LifeSciences #Biotech #Pharma #MedTech #ClinicalResearch #XtalksCommunity #Leadership
Qubigen retweeted
Qubigen is proud to announce that Dr Jun Zeng, Co-Founder and Chief Information Officer, has been elected as a Fellow of the Royal Australian Chemical Instituteย (FRACI), the highest professional membership grade awarded by the Institute. qubigen.com/post/qubigen-co-โฆ
Qubigen retweeted
๐Qubigen is helping to crack the world's toughest diseases by fostering a collaborative federated data approach for new medicines that no single company could develop on their own.
โ๏ธWhat's a specific diseases that you would love to see cured in our life time?
Qubigen retweeted
๐ฆพWe're looking to #SummerSlam hard into difficult 'undruggable' diseases.
๐ง Qubigenโs Federated AI and quantum chemistry platform unlocks global drug design data without exposing its secrets, enabling partners to collaborate on groundbreaking medicines for the toughest diseases.
Which diseases is worthy of being punched up nextโ๏ธ๐
Qubigen retweeted
Good reasoning engines need quality data to train on.
With drug design, generic public data wonโt cut it.
The best data are locked behind institutional firewalls and Big Pharma ๐
Federated AI ๐ค could be the solution to unlock medicines unachievable in a single company
We released two open-weight reasoning modelsโgpt-oss-120b and gpt-oss-20bโunder an Apache 2.0 license.
Developed with open-source community feedback, these models deliver meaningful advancements in both reasoning capabilities & safety.
openai.com/index/introducingโฆ
Qubigen retweeted
At Qubigen, we're rewriting the rules of how new medicnes are discovered, and weโre inviting the world to join us.
๐ฎImagine slashing drug design timelines from years to just weeks - tackling the toughest diseases with a global, collaborative approachโwithout ever compromising sensitive data.
Weโre making it happen with our cutting-edge Federated AI and quantum chemistry platform.
โผ๏ธHereโs the problem: Big Pharmaโs best data can hold the key to breakthroughs, but it sits locked behind proprietary firewalls. Traditional AI models like those built on public data (sorry, AlphaFold) canโt touch it.
Outdated, limited datasets just donโt cut it for the next generation of medicines.
๐ง ๐คEnter Qubigen. Our patented Federated AI technology lets research institutes, biotechs, and pharma giants collaborate securely across the globe, analyzing proprietary datasets without exposing background IP. Pair that with our GPU-accelerated virtual screening and quantum chemistry tools, and weโre not just designing drugs fasterโweโre creating the largest, most intelligent, disease-agnostic computational toolbox for AI-driven drug design ever. ๐งช
Qubigen retweeted
๐Groundbreaking open-source paper alert!
Qubigen's Federated AI is a game-changer for training AI on global, decentralized data securely!
๐Key points:
- Privacy-first: No transfer of external needed.
- Matches centralized AI accuracy, and in cases of dirty data, can exceed it!
-Outperforms traditional methods on messy healthcare data.
-Clustering optimization slashes model transfer costs.
Check it out:
nature.com/articles/s41598-0โฆ
Qubigen retweeted
Qubigen Advances in the TBXT Challenge with Promising Early Compounds and Second-Round AI Optimization Underway
qubigen.com/post/qubigen-advโฆ
Qubigen retweeted
Replying to @DrJMMHall
Qubigen's got the keys to Big Pharma's vault. Game changer! ๐ฅ
Qubigen retweeted
๐จ โผ๏ธ Reminder! We could see a massive shift in AI. GROK 4 can do great as a reasoning engine, and on generic, public data sources. But that simply wonโt work for designing new medicines - as the relevant data is behind institutional firewalls that only Qubigen could accessโฆ
Qubigen retweeted
Replying to @DrJMMHall
Qubigen's federated learning enables collaborative AI training on decentralized, private datasets without data sharing, preserving IP and privacy. This gives it an edge in drug design by accessing exclusive pharma data for more accurate, novel molecule generationโunlike centralized LLMs like Grok or ChatGPT, which rely on public data and lack real-time proprietary integration. Scalable and cost-effective, it accelerates therapeutics discovery.
Qubigen retweeted
๐๐๐ช๐๐๐๐๐ฃ ๐๐จ ๐๐๐๐๐ก๐๐ง๐๐ฉ๐๐ฃ๐ ๐ฉ๐๐ ๐๐ช๐ฉ๐ช๐ง๐ ๐ค๐ ๐๐๐๐๐ง๐๐ฉ๐๐ ๐ผ๐ for drug design, and weโre on the hunt for a visionary lead investor to join our journey!
Our innovative platform is transforming biotech ๐งซ, and weโve already secured strategic pre-seed funding from SYNthesis BioVentures, with a second tranche unlocked ahead of schedule due to groundbreaking results.
Be part of a mission to revolutionize precision medicine...
๐๐ค๐ก๐ก๐๐๐ค๐ง๐๐ฉ๐๐ค๐ฃ ๐ฌ๐๐ฉ๐๐ค๐ช๐ฉ ๐ง๐๐ซ๐๐๐ก๐๐ฃ๐ ๐จ๐๐๐ง๐๐ฉ๐จ
Learn more about our progress and connect with us to explore this exciting investment opportunity:
โข Qubigen Secures Pre-Seed Investment: shorturl.at/Sk8Bm
โข Second Tranche Unlocked Early: shorturl.at/R0l7Y
DM us or visit qubigen.com to get involved!
#AI #DrugDiscovery #InvestmentOpportunity #HealthcareInnovation #Science
Qubigen retweeted
Researchers from the Parkinsonโs Disease Research Centre at WEHI & the National Drug Discovery Centre have discovered a molecule that blocks cell death, a finding that could lead to next-generation drugs for neurogenerative condition.
wehi.edu.au/news/cell-death-โฆ



























